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Assessment of Angiotensin II Receptor
Blockade in Humans Using a Standardized
Angiotensin II Receptor-Binding Assay
Marc P. Maillard, Lucia Mazzolai, Ve´ronique Daven, Catherine Centeno, Ju¨rg Nussberger,
Hans-R. Brunner, and Michel Burnier
An in vitro angiotensin II (AngII) receptor-binding
assay was developed to monitor the degree of
receptor blockade in standardized conditions. This
in vitro method was validated by comparing its
results with those obtained in vivo with the
injection of exogenous AngII and the measurement
of the AngII-induced changes in systolic blood
pressure. For this purpose, 12 normotensive subjects
were enrolled in a double-blind, four-way cross-over
study comparing the AngII receptor blockade
induced by a single oral dose of losartan (50 mg),
valsartan (80 mg), irbesartan (150 mg), and placebo.
A significant linear relationship between the two
methods was found (r 5 0.723, n 5 191, P < .001).
However, there exists a wide scatter of the in vivo
data in the absence of active AngII receptor
blockade. Thus, the relationship between the two
methods is markedly improved (r 5 0.87, n 5 47,
P < .001) when only measurements done 4 h after
administration of the drugs are considered
(maximal antagonist activity observed in vivo)
suggesting that the two methods are equally
effective in assessing the degree of AT-1 receptor
blockade, but with a greatly reduced variability in
the in vitro assay. In addition, the pharmacokinetic/
pharmacodynamic analysis performed with the
three antagonists suggest that the AT-1 receptor-
binding assay works as a bioassay that integrates
the antagonistic property of all active drug
components of the plasma. This standardized in
vitro-binding assay represents a simple, reproducible,
and precise tool to characterize the pharmacodynamic
profile of AngII receptor antagonists in humans.
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Blockade of the renin-angiotensin system cas-cade with angiotensin converting enzyme(ACE) inhibitors is an effective therapeuticapproach to the treatment of hypertension
and congestive heart failure.1 More recently, angioten-
sin II (AngII) receptor antagonists, which block the
binding of Ang II to its AT-1-receptor, have become an
interesting alternative to the use of ACE inhibitors.2
Since the original characterization of losartan, the first
nonpeptide orally active AT-1 receptor antagonist,
several new compounds have been developed that
demonstrate a high affinity and selectivity for the
AT-1 receptor subtype.3
In the 1970s and 1980s, the first evidence that ACE
inhibitors block the renin-angiotensin system in hu-
mans were obtained by demonstrating that these com-
pounds were able to blunt the blood pressure re-
sponse to exogenous AngI but not to AngII.4,5 A
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similar approach has been used recently for the early
clinical investigation of AngII antagonists. Thus, the
pharmacodynamics (PD) of several AT-1 antagonists
have been characterized assessing their ability to block
the blood pressure response to exogenous AngII.6–10
This approach has enabled to gain valuable informa-
tion on the minimal effective dose of each compound
and on the time profile of the drug-induced receptor
blockade.
The administration of exogenous AngII remains a
rather invasive and complex way to evaluate the de-
gree of AngII receptor blockade. Therefore, this ap-
proach is never used in hypertensive patients. Deter-
mination of the reactive increase in plasma renin
activity or plasma AngII levels could represent an
alternative way to monitor indirectly AngII receptor
blockade after administration of an antagonist.6 How-
ever, these parameters are characterized by their indi-
vidual variability due mainly to the heterogeneity of
sodium intake and renal sodium handling by hyper-
tensive patients.
In the present article, we describe an in vitro AngII
receptor-binding assay that enables to monitor the
degree of receptor blockade in standardized condi-
tions. When compared to the in vivo method using the
injection of exogenous AngII, the in vitro receptor-
binding assay produces similar results but with a
greatly reduced variability. This standardized assess-
ment of antagonistic effect of drug active components
in human plasma represents a simple and precise new
tool to characterize the PD profile of AngII receptor
antagonists in normotensive subjects as well as in
hypertensive patients.
METHODS AND SUBJECTS
In Vitro Assessment of AngII Receptor-Binding As-
say The receptor-binding assay is conducted on rat
smooth muscle cell membranes expressing solely the
angiotensin AT-1 receptor subtype.11 To obtain cell
membranes, rat aortic smooth muscle cells (SMC) are
cultured in Dulbecco’s modified eagle medium (Gibco
BRL, Life Technologies, Paisley, UK) with 15% fetal
calf serum (Seromed SO115, Fakola AG, Basle, Swit-
zerland). When achieving about 90% confluence, the
cells are scratched with a rubber policeman, recov-
ered, and homogenized in an ice-cold buffer contain-
ing 0.25 mol/L sucrose, 5 mmol/L Tris/HCl, 5
mmol/L EDTA, pH 7.4, and a protease inhibitor cock-
tail (Complete, Boehringer Mannheim, Germany). The
suspension is centrifuged at 50,000 g for 30 min at 4°C.
The pellet is resuspended in a binding buffer contain-
ing 50 mmol/L Tris/HCl and 5 mmol/L EDTA at pH
7.4 and centrifuged a second time as described above.
The membrane pellet is finally resuspended in the
binding buffer at 1 mg of protein/mL, aliquoted,
quick frozen in liquid N2, and stored at 270°C. Cells
are used after 5 to 17 passages. The protein content of
the pellet is determined using the bicinchoninic acid
protein assay (Pierce, Rockford, IL).
The receptor binding is performed at 37°C for 1 h
with 100 mg membrane proteins in 375 mL binding
buffer in the presence of 5 fmol of labeled AngII
(angiotensin II (5-l-isoleucine) tyrosyl-125I-monoiodi-
nated; DuPont, Boston, MA) and 25 mL of human
plasma. The blanks and the standard curve are per-
formed using 25 mL of a reference plasma (RP). In the
present experiments, the RP consists of a pool of dif-
ferent plasmas obtained from healthy untreated vol-
unteers. This plasma is stored at 270°C and thawed
before use in the same conditions as the tested plasma.
Nonspecific binding (B0) is estimated by adding 10
mmol/L of unlabeled human AngII (Peninsula, Bel-
mont, CA) to the incubation mixture. Separation of
bound labeled AngII is achieved by centrifugation and
residual radioactivity (B) determined by gamma
counting. To compare the activity of different antago-
nists, the results are normalized and expressed as (B 2
B0)/(BRP 2 B0) where BRP is the residual activity in the
presence of the RP. Within each assay, separate com-
petition-binding curves are performed with cold An-
gII and with the AT-1 receptor antagonist losartan to
assess the reproducibility of the method and the qual-
ity of the membranes.
The precision of the method has been assessed by
repeated measurements of plasma samples from sev-
eral subjects in one assay using the same batch of SMC
membrane preparation (within-assay precision) or in
several assays with different batches of SMC mem-
brane preparations and of labeled AngII (between-
assay precision). The reproducibility (R) of the method
has been estimated by analyzing the results obtained
with the plasmas of 12 volunteers collected at times 0,
4, 24, and 30 h after administration of a placebo. These
plasmas contained no AngII receptor antagonist sus-
ceptible to displace binding of 125I–AngII. The repro-
ducibility is calculated as a mean coefficient of varia-
tion using the following formula:
R 5 ˛2 O
i51
n ~CVi!2
n ,
where CV is the coefficient of variation in subject i for
three time different measures and n the number of
volunteers. The same formula has been used to calcu-
late the reproducibility of the in vivo method.
Comparison of the In Vitro With the In Vivo Assess-
ment of AngII Receptor Blockade To validate the
use of the in vitro AngII receptor-binding assay, the
results obtained in vitro were compared to those gath-
ered in vivo with the injection of exogenous AngII and
the measurement of the AngII-induced changes in
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systolic and diastolic blood pressures. To this purpose,
blood was collected in 12 normotensive subjects en-
rolled in a double-blind, placebo-controlled, four-way
cross-over study dedicated to the comparison of the
AngII receptor blockade induced by a single oral dose
of losartan (50 mg), valsartan (80 mg), and irbesartan
(150 mg).12 Blood was collected before the administra-
tion of each compound and 4, 24, and 30 h after drug
intake into 2.7 mL of S-Monovette KE (Sarstedt, Nu¨m-
brecht, Germany) containing 1.6 mg of EDTA/mL.
Blood was taken systematically before the administra-
tion of exogenous AngII.
The in vivo assessment of AngII receptor blockade
was performed as reported previously.6 Briefly, a pre-
determined dose of exogenous AngII increasing sys-
tolic blood pressure by 25 to 40 mm Hg is adminis-
tered intravenously before and 4, 24, and 30 h after
drug intake. Blood pressure is measured and recorded
continuously at the finger by photoplethysmography
(Finapres, Ohmeda, Englewood, CO) shortly before
and during several minutes after each injection of
AngII and the peak blood pressure changes are calcu-
lated.13
The in vivo and in vitro methods were compared by
analyzing the relationship between the in vivo assess-
ment of AngII receptor blockade expressed as the
percentage of the baseline systolic blood pressure re-
sponse to AngII and the percentage displacement of
125I–AngII in the in vitro assay.
Relationship Between Plasma Drug Levels and
AngII Receptor Blockade Plasma drug levels were
measured on time 0, 4, 24, and 30 h. Hence, the rela-
FIGURE 1. Specific 125I–AngII binding in rat aortic SMC
membrane preparation in presence of unlabeled AngII with either
25 mL of BSA 7% (a) or 25 mL of human plasma (b).
FIGURE 2. Comparison of the in vivo and in vitro methods by
analyzing the relationship between the in vivo assessment of AngII
receptor blockade expressed as the percentage of the baseline sys-
tolic BP response to AngII and the percentage of labeled AngII in
the in vitro assay. (A) All data (ie, AngII antagonistic activities
measured in all volunteers, before and 4, 24, and 30 h after drug
intake, within the four treatments). Linear regression: Y 5 0.670
(60.046) 3 127.33 (63.75) (r 5 0.723; n 5 191; P , .0001). (B)
Data acquired during AngII receptor blockade, 4 h after drug
intake. Linear regression: Y 5 0.983 (60.081) 3 12.28 (64.59)
(r 5 0.876; n 5 47; P , .0001).
TABLE 1. PRECISION OF THE IN VITRO ASSAY
Samples
Percent 125I-Ang II-Specific
Binding
Mean SD
Coefficient of
Variation (%)
Within-assay precision
(n 5 10)
Plasma 1 90 4.5 5.0
Plasma 2 68 3.2 4.3
Plasma 3 2.0 0.2 10.3
Between-assay precision
(n 5 7)
Plasma 4 104.0 8.6 8.3
Plasma 5 55.0 1.7 3.0
Plasma 6 4.7 1.6 34.9
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tionship between the pharmacokinetic (PK) and the
PD effects of the AngII antagonists could be examined.
To this purpose, individual values of the plasma drug
concentrations were plotted against the individual PD
variables and analyzed in a descriptive way. The
PK/PD relationships were assessed with the percent-
age inhibition of the effects of the predefined dose of
AngII (in the in vivo approach) and of the binding of
labeled-AngII in the in vitro assay. Two models were
used to describe the PK/PD: a log-linear model, where
the effect is related to the log of the plasma concen-
tration and an Emax model fitting with the Hill sigmoid
curve given as follows14: E 5 (C 3 Emax)/(C 1 EC50),
where C is the drug level in the plasma, EC50 is the
drug concentration that produces half the maximal
effect, and Emax is theoretic maximal effect observable.
The PK/PD relationship of losartan was more com-
plex to assess as this AngII antagonist is metabolized
in the liver to EXP3174, a metabolite that represents
the major active component of losartan potassium.7
Therefore, the PK/PD analysis was performed with
plasma EXP3174 alone and also considering both
plasma losartan and EXP3174 levels. To take into ac-
count the relative affinity of each active components to
the AT-1 receptor, the respective concentration of lo-
sartan and EXP-3174 were expressed as concentration
equivalents and were presented as multiples of the
concentration at which 50% of receptors were occu-
pied by the antagonists (n 3 Ki).15 It should be men-
tioned that in contrast to the concentration, the con-
centration equivalent is given without dimension.
Statistical Analysis The correlation coefficients were
calculated by the least square method. The in vitro/in
vivo comparison was done by a one-way ANOVA. A
one population t test was also performed on the mean
difference (in vitro 2 in vivo) to analyze the difference
from 0. All values are expressed as mean 6 SEM
unless otherwise indicated. A P value , .05 is consid-
ered as significant. Hill sigmoid curves fitting are per-
formed with the solver tool of Microsoft Excel version
7.0 (Microsoft Corporation, Redmond, WA). Emax and
EC50 are estimated by an iterating procedure minimiz-
ing the sum of squared differences between calculated
and observed effect values.
RESULTS
Characteristics of the In Vitro Receptor-Binding As-
say A typical 125I–AngII displacement curve by un-
labeled AngII in a rat aortic SMC preparation is shown
in Figure 1. In the presence of 25 mL of a 7% bovine
serum albumin (BSA) solution, the half-maximal inhi-
bition concentration (IC50) is 3.1 6 0.2 nmol/L. The
substitution of BSA by 25 mL of the human RP con-
taining no drug does not significantly modify the
curve (IC50 shifted to 2.5 6 0.1 nmol/L) (Figure 1). In
the same assay, the AT-1 antagonist DUP753 (losartan)
inhibits the binding of radiolabeled AngII with an IC50
of 10.7 6 2.2 nmol/L. To determine the effect of the
protein content on the displacement of 125I–AngII by
an AngII antagonist, displacement curves were carried
out with losartan in assays containing increasing con-
centrations of albumin in the binding buffer. With
protein concentrations ranging between 45 and 90
g/L, no significant effect of the protein content on the
displacement curve was found.
Table 1 summarizes the results obtained by 10 mea-
surements of three different plasma samples covering
a large range of antagonistic activity (within-assay
precision). The coefficient of variation varied between
4.3% and 10.3% depending on the degree of antago-
nistic activity. For active plasmas with a low percent-
age of 125I–AngII-specific binding, the variation is
higher but with a very small imprecision on the mea-
surement of bound labeled AngII. Between-assay pre-
cision evaluated on three samples measured repeat-
edly in seven consecutive assays ranges between 3.0%
and 8.3% for plasma showing either no or little antag-
onistic activity. The CV increased to 35% with samples
exhibiting an almost complete antagonistic activity.
Comparison With the in Vitro Assessment of AngII
Receptor Blockade With the In Vivo Approach Fig-
ure 2A shows the relationship existing between the
TABLE 2. RELATIONSHIPS BETWEEN PLASMA DRUG LEVELS AND INHIBITORY EFFECT
Model
Valsartan Irbesartan
In Vivo Assay In Vitro Assay In Vivo Assay In Vitro Assay
log/lin A 5 23.70 A 5 237.83 A 5 9.75 A 5 24.19
B 5 21.86 B 5 32.96 B 5 25.60 B 5 35.56
E 5 A 1 B*Log (C) r 5 0.475 r 5 0.922 r 5 0.649 r 5 0.951
Hill sigmoid Emax 5 78% Emax 5 75% Emax 5 83% Emax 5 100%
E 5
C p Emax
C 1 EC50
EC50 5 63.9 ng/ml EC50 5 193.4 ng/ml EC50 5 24.3 ng/ml EC50 5 34.7 ng/ml
SS 5 1.6717 SS 5 0.6784 SS 5 1.1552 SS 5 0.1239
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percent inhibition of systolic blood pressure in re-
sponse to exogenous AngII measured in vivo and the
percentage of bound radiolabeled AngII in vitro. A
significant linear relationship between the two meth-
ods is found (r 5 0.723, n 5 191, P , .001). However,
the figure demonstrates that there is a wide scatter of
the in vivo data when no in vitro AngII receptor
blockade is measured. Figure 2B shows the relation-
ship between the two methods when only measure-
ments done 4 h after administration of the AngII an-
tagonists are considered (maximal antagonist activity
observed in vivo). In this case, the relationship is
markedly improved (r 5 0.87, n 5 47, P , .001)
suggesting that as soon as some blockade of the AngII
receptor occurs, the two methods are equally effective
in assessing the degree of AT-1 receptor blockade.
Noteworthy, the slope of the regression curve is close
to 1 and the intercept is near 0, indicating that the
curve almost fits with the identity line. Statistically, no
significant difference between values measured with
the two approaches was found.
Our results suggest, however, that the in vivo ap-
proach has a greater variability than the in vitro
method. When the methods are compared 4, 24, and
30 h after the administration of a placebo, the variabil-
ity of the blood pressure response to exogenous AngII
is close to 40%, whereas the variation of the inhibition
of 125I–AngII binding is only 7% with the in vitro
assay. In this study, the mean overall intraindividual
CV for repeated measurements was, respectively,
25.4 6 2.7% (n 5 12; range, 8% to 40%) with the in vivo
method and 5.2 6 2.4% (range, 1% to 9 %) with the in
vitro receptor-binding assay. The overall reproducibil-
ity of both methods was, respectively, 28.1% and 5.6%
for the in vivo and the in vitro assessments of AngII
receptor blockade.
The variability of the blood pressure response to
exogenous AngII appears to be lower when several
injections of the same dose of AngII are administered
within a shorter time. Thus, when defining the dose of
AngII increasing systolic blood pressure by 25 to 40
mm Hg, three consecutive injections of the same
amount of angiotensin were administered to our sub-
jects at 30-min intervals. Under these conditions, the
mean intraindividual CV of the blood pressure re-
sponse was 13.4 6 1.1% (range, 2.1% to 43%) and the
overall reproducibility of the in vivo method esti-
mated at 13.9%.
Use of the In Vitro Receptor-Binding Assay in
PK/PD Analysis Table 2 shows the PK/PD relation-
ships of valsartan, irbesartan, and losartan in the 12
normotensive subjects. Plasma drug levels were cor-
related either with the percentage changes in blood
pressure response to exogenous AngII or with the
results of the in vitro receptor-binding assay in the
two analytical models chosen for assessing PK/PD
relationships of AngII antagonists. With valsartan and
irbesartan, the PK/PD relationship was significantly
improved by the use of the in vitro data with r val-
ues . 0.9 in the log/linear model (see Figure 3) and
very low sum of squares values in the Emax model (see
Table 2). Estimation of the PK/PD profile of losartan
using plasma EXP3174 levels gave poor results with
the in vivo data as no significant correlation was
found with the log/linear or the Emax model. When
analyzed based on the in vitro data, the PK/PD pro-
files of losartan were more consistent with the models
used. The fitting with both models was still improved
when the sum of all active drug components present
in plasma was taken into account (ie, EXP3174 and
plasma losartan levels, expressed as the sum of their
TABLE 2. CONTINUED
Model
Losartan (EXP3174) Losartan (EXP3174 1 Losartan)
In Vivo Assay In Vitro Assay In Vivo Assay In Vitro Assay
log/lin A 5 9.17 A 5 230.30 A 5 5.98 A 5 239.03
B 5 13.8 B 5 42.02 B 5 13.86 B 5 41.51
E 5 A 1 B*Log
(C) r 5 0.313 r 5 0.770 r 5 0.321 r 5 0.872
Hill sigmoid Emax 5 41% Emax 5 100% Emax 5 40% Emax 5 99%
E 5
C p Emax
C 1 EC50
EC50 5 8.9 ng/ml EC50 5 75.5 ng/ml EC50 5 12.7* EC50 5 134.6*
SS 5 1.2222 SS 5 0.3051 SS 5 1.2675 SS 5 0.2955
E, Effect expressed in percentage inhibition (resp. AngII response in vivo and 125I-AngII binding in vitro); C, plasma concentration of drug [ng/mL] or
* expressed as concentration equivalents (n 3 Ki).
In log/lin model, A and B, respectively, represent the intercept and the slope of the constructed regression line, and r is the correlation coefficient of this
line.
In the Hill sigmoid model, Emax represents the theoretical maximal inhibition; EC50 5 drug concentration that produces half the maximal effect; SS 5
sum of squares of the difference between Emeasured and Eestimated on the Hill sigmoid curve.
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respective concentration equivalents). In these condi-
tions, closer relationships were observed (with r value
approaching 0.9 [P , .001] in the log/linear model and
lower SS values in the Emax model).
DISCUSSION
This article presents an in vitro AngII receptor-bind-
ing assay that enables to assess the AT-1 receptor
antagonistic effect of human plasma in well-standard-
ized conditions. When compared with the in vivo
approach that uses the injection of exogenous AngII to
evaluate the degree of AngII receptor blockade, this
assay produces comparable quantitative results in
subjects receiving an AngII receptor antagonist but
with a greatly reduced inter- and intraindividual vari-
ability. The PK/PD analysis performed with three
antagonists suggests that the AT-1 receptor-binding
assay works as a bioassay that integrates the antago-
nistic property of all active drug components of the
plasma (ie, active drug and active metabolite). This in
vitro-binding assay that avoids the use of exogenous
AngII represents a simple, reproducible, and precise
new tool to characterize the PD profile of AngII recep-
tor antagonists in humans.
The in vitro receptor-binding assay offers several
advantages over the past techniques used to evaluate
a drug-induced blockade of AngII receptors. First, the
assay is specific as it is performed on vascular smooth
muscle cells that contain only AT-1 and no AT-2 re-
ceptors, as demonstrated previously.11 Second, the use
of a membrane preparation allows to prepare a large
amount of material at one time and to keep the mem-
branes frozen without damage. Thus, the same batch
of membranes can be used throughout a study,
thereby reducing, considerably, the interassay vari-
ability. A similar assay has been developed recently
using rat lung tissue.16 The advantage of rat SMCs is
that they are now commercially available and easy to
grow in culture. As shown in previous experiments
and again in this study, the IC50 for cold AngII and
losartan is in the low nanomolar range.17,18 These
values reflect the integrity of AT-1 receptors in the
membrane preparation. Thus, these parameters can be
used as internal quality controls.
The addition of 25 mL of human plasma to the
binding buffer does not interfere with the characteris-
tics of the 125I–AngII displacement curve. Although
human plasma contains AngII, its endogenous con-
centration stays at levels that do not interfere with the
competition binding measured in the assay (between 2
fmol/mL before the administration of any drug and
about 40 fmol/mL during maximal AngII receptor
blockade). In addition, the presence of EDTA in
plasma samples and in binding buffer prevents enzy-
matic production of AngII or degradation of drugs
during the incubation process.19 The small amount of
plasma needed to perform the assay certainly repre-
sents another advantage of the method. Indeed, this
enables to perform several measurements in the same
individual and thereby to improve the PD character-
ization of an AngII receptor antagonist.
When compared with the results obtained in vivo
with the administration of exogenous AngII, the data
gathered with the in vitro assay appear to be quanti-
tatively similar and no significant difference was
found between the two methods. Yet, the reproduc-
ibility of the in vitro assay is markedly better at 5% to
6%. The greater variability of the in vivo approach is
not entirely surprising. The blood pressure response
to exogenous AngII is known to differ markedly be-
tween individuals and to vary during the day. Other
factors, such as meals and the subject’s emotional
response, can contribute to the variability of the blood
pressure response to exogenous AngII. Interestingly,
FIGURE 3. Relationships between plasma drug levels and in-
hibitory effect. The effect (percentage of blockade of the pressor
response to AngII in the in vivo approach [open symbols], and
percentage of 125I–Ang II displaced from receptor in the radiore-
ceptor assay [solid symbols]) is related to the log of the plasma
concentration of (A) valsartan (E/F), (B) irbesartan (h/n ), or (C)
losartan and EXP-3174 (/). The drug concentrations are ex-
pressed in ng/mL for valsartan and irbesartan and in concentra-
tion equivalents (n 3 Ki) for the sum of losartan and EXP-3174
(see explanation in text).
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the results obtained with the injections of AngII cor-
relate very well with the in vitro data when an AT-1
receptor antagonist is administered. This suggests that
the reproducibility of the in vivo method is improved
as soon as there is a partial or complete blockade of
AT-1 receptors. The variability of the in vivo method
is also reduced when several injections of AngII are
performed within a short time. In this study, exoge-
nous AngII was injected up to 30 h after drug intake.
This may explain why the variability of the in vivo
approach was higher. Of course, the main advantage
of the in vitro receptor-binding assay is that an ade-
quate evaluation of AngII receptor blockade can be
obtained without the administration of AngII. This is
of particular interest when conducting PD studies di-
rectly in hypertensive patients. In addition, the very
low variability of the method should enable to obtain
reliable results with only a small number of subjects.
Irbesartan and valsartan are two AngII receptor an-
tagonists that have no active metabolite. When the
degree of AngII receptor blockade measured with the
in vitro assay after administration of these two agents
was correlated with plasma drug levels in two differ-
ent PK/PD models, excellent correlations were found
suggesting that the in vitro assay works as a bioassay
assessing the overall antagonistic capacity of the
tested plasma. This is further supported by our data
using losartan. Indeed, when the PK/PD modelization
was performed with the plasma levels of the active
metabolite EXP3174 only, poor relationships were ob-
tained. However, significant correlations were ob-
served when the effect was correlated with the plasma
content of both active components of the drug (ie,
losartan and its principal metabolite EXP3174). The
PD parameters (Emax and EC50) measured in our study
were in good agreement with those already published
in the literature where Mu¨ller et al8 estimated the
theoretic maximum effect for valsartan to be 74% with
an EC50 of about 200 ng/mL or for losartan where
Emax of 91% and EC50 of 35 ng/mL were calculated.
7
To our knowledge, no data were published yet for
irbesartan.
Whether the assay reflects only the activity of the
free components of plasma drug levels is difficult to
ascertain from our studies. The results of the PK/PD
analysis calculated with the in vitro data are very
comparable to those published previously with differ-
ent PD assessments of AngII receptor blockade.20
In conclusion, this study presents a new in vitro
AT-1 receptor-binding assay that enables to evaluate
AngII receptor blockade with a high specificity and a
very low variability. By avoiding the use of exogenous
AngII, this method provides the opportunity to obtain
standardized PD data in healthy subjects as well as in
hypertensive patients.
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